{"id":"adt-second-generation-antiandrogens-chemotherapy","safety":{"commonSideEffects":[{"rate":"50–80","effect":"Hot flashes"},{"rate":"40–60","effect":"Fatigue"},{"rate":"40–70","effect":"Sexual dysfunction/erectile dysfunction"},{"rate":"10–20","effect":"Gynecomastia"},{"rate":"20–40","effect":"Nausea"},{"rate":"15–30","effect":"Diarrhea (with second-generation antiandrogens)"},{"rate":"30–50","effect":"Neutropenia (if chemotherapy included)"},{"rate":"20–40","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL5858588","moleculeType":null,"molecularWeight":"430.62"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Androgen deprivation therapy (ADT) reduces circulating testosterone, while second-generation antiandrogens (such as enzalutamide, abiraterone, or apalutamide) block androgen receptor function at the cellular level. The optional addition of chemotherapy (typically docetaxel) provides direct cytotoxic activity against rapidly dividing cancer cells. This multi-modal approach targets hormone-sensitive and castration-resistant prostate cancer through complementary mechanisms.","oneSentence":"This combination suppresses androgen production and blocks androgen receptor signaling in prostate cancer cells, with optional chemotherapy to enhance cytotoxic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:57.761Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic hormone-sensitive prostate cancer"},{"name":"Castration-resistant prostate cancer (with second-generation antiandrogens)"}]},"trialDetails":[{"nctId":"NCT06350825","phase":"PHASE3","title":"Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-01-01","conditions":"Metastatic Prostate Cancer, Therapy, Directly Observed","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1542,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["hormonal therapy or chemotherapy"],"phase":"phase_3","status":"active","brandName":"ADT+second-generation antiandrogens ± chemotherapy","genericName":"ADT+second-generation antiandrogens ± chemotherapy","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination suppresses androgen production and blocks androgen receptor signaling in prostate cancer cells, with optional chemotherapy to enhance cytotoxic effects. Used for Metastatic hormone-sensitive prostate cancer, Castration-resistant prostate cancer (with second-generation antiandrogens).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}